Puma Biotech Drug Patent Portfolio
Puma Biotech owns 1 orange book drug protected by 11 US patents Given below is the list of Puma Biotech's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8669273 | Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine | 18 Jul, 2031 | Active |
| US7399865 | Protein tyrosine kinase enzyme inhibitors | 29 Dec, 2030 | Active |
| US8518446 | Coated tablet formulations and uses thereof | 20 Nov, 2030 | Active |
| US8790708 | Coated tablet formulations and uses thereof | 05 Nov, 2030 | Active |
| US9211291 | Treatment regimen utilizing neratinib for breast cancer | 24 Mar, 2030 | Active |
| US9265784 | Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine | 04 Aug, 2029 | Active |
| US10035788 | Maleate salts of (E)-N-{4[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof | 15 Oct, 2028 | Active |
| US9139558 | Maleate salts of (E)-N-{4-[3-Chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof | 15 Oct, 2028 | Active |
| US9630946 | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof | 15 Oct, 2028 | Active |
| US7982043 | Protein tyrosine kinase enzyme inhibitors | 08 Oct, 2025 | Active |
| US6288082 | Substituted 3-cyanoquinolines | 24 Sep, 2019 | Expired |
Latest Legal Activities on Puma Biotech's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Puma Biotech.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 09 Aug, 2023 | US9265784 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 31 May, 2023 | US9211291 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 08 Mar, 2023 | US9139558 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 06 Jan, 2023 | US7982043 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 19 Jan, 2022 | US10035788 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 12 Jan, 2022 | US8790708 |
|
Patent Term Extension Certificate
Critical
| 19 Nov, 2021 | US7399865 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 04 Oct, 2021 | US7399865 |
|
Email Notification
Critical
| 04 Oct, 2021 | US7399865 |
|
Correspondence Address Change
Critical
| 03 Oct, 2021 | US7399865 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 25 Aug, 2021 | US8669273 |
| Notice of Final Determination -Election Required | 22 Feb, 2021 | US7399865 |
| Notice of Final Determination -Election Required | 22 Feb, 2021 | US9211291 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 10 Feb, 2021 | US8518446 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 24 Sep, 2020 | US9630946 |
Puma Biotech Drug Patents' Oppositions Filed in EPO
Puma Biotech drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Aug 03, 2016, by Hexal Ag. This opposition was filed on patent number EP10722215A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP10779339A | May, 2020 | Cooke, Richard | Patent maintained as amended |
| EP09791127A | Oct, 2017 | Hexal AG | Granted and Under Opposition |
| EP10722215A | Aug, 2016 | Hexal AG | Revoked |
Puma Biotech's Family Patents
Puma Biotech drugs have patent protection in a total of 33 countries. It's US patent count contributes only to 13.1% of its total global patent coverage. 4 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Puma Biotech Drug List
Given below is the complete list of Puma Biotech's drugs and the patents protecting them.
1. Nerlynx
Nerlynx is protected by 11 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8669273 | Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine |
18 Jul, 2031
(6 years from now)
| Active |
| US7399865 | Protein tyrosine kinase enzyme inhibitors |
29 Dec, 2030
(6 years from now)
| Active |
| US8518446 | Coated tablet formulations and uses thereof |
20 Nov, 2030
(5 years from now)
| Active |
| US8790708 | Coated tablet formulations and uses thereof |
05 Nov, 2030
(5 years from now)
| Active |
| US9211291 | Treatment regimen utilizing neratinib for breast cancer |
24 Mar, 2030
(5 years from now)
| Active |
| US9265784 | Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine |
04 Aug, 2029
(4 years from now)
| Active |
| US10035788 | Maleate salts of (E)-N-{4[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
15 Oct, 2028
(3 years from now)
| Active |
| US9139558 | Maleate salts of (E)-N-{4-[3-Chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
15 Oct, 2028
(3 years from now)
| Active |
| US9630946 | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
15 Oct, 2028
(3 years from now)
| Active |
| US7982043 | Protein tyrosine kinase enzyme inhibitors |
08 Oct, 2025
(9 months from now)
| Active |
| US6288082 | Substituted 3-cyanoquinolines |
24 Sep, 2019
(5 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Nerlynx's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List